Keywords: Diagnosis/Prediction, Cancer, Spectroscopy; NMR; Prediction; Metabolomics
Motivation: Malignant melanoma is an aggressive skin cancer, typically associated with a poor prognosis due to distant, invasive metastasis that are often challenging to diagnose.
Goal(s): We wished to see if a previously-applied whole-blood MR metabolomics classification algorithm could distinguish patients with distant metastasis from those with only locally advanced disease
Approach: We have recently received consent to undertake this trial on 200 melanoma patients who may have undiagnosed distant metastasis at the time of sampling. We undertook 600MHz CPMG spectroscopy on whole blood and will subsequently perform cross-validated OPLS-DA on 0.01ppm spectral buckets in an attempt to build a clinically-useful classifier.
Impact: Patients with resected AJCC stage IIB/C and III cutaneous melanoma are at high risk of recurrent disease with poor prognosis. An inexpensive blood biopsy able to predict those with distant metastatic disease would guide clinical decision making and save lives.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords